The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Improving Clinical Care In Patients With Cirrhosis
Funder
National Health and Medical Research Council
Funding Amount
$132,743.00
Summary
This PhD will evaluate the current state of cirrhosis care in Australia. Part one aims to determine the community prevalence of cirrhosis in a general practice cohort and assess the proportion of patients that have been already diagnosed. Part two will evaluate if patients with established compensated cirrhosis are receiving appropriate care and if not assess barriers to care. Part three will evaluate biomarkers to predict the risk of decompensation in patients with established cirrhosis.
Cardiac Dysfunction In Advanced Liver Disease And After Liver Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Heart disease is the leading cause of early death after liver transplantation (LT). The scarcity of donor organs means that LT is a limited and valuable resource. We propose screening for heart disease before LT by CT scanning of heart arteries and heart function on stress testing to improve detection of coronary heart disease (CHD). Follow-up CT scans will also assess if LT causes progression of CHD. These studies will aid in development of personalised treatment strategies to improve outcomes.
A Dietary Intervention For Sarcopenia In Cirrhosis
Funder
National Health and Medical Research Council
Funding Amount
$128,224.00
Summary
Patients with chronic liver failure, or cirrhosis, suffer many complications. Sarcopenia, the loss of muscle and muscle weakness, is one of these. It is associated with reduced survival. Patients with cirrhosis have low levels of branched chain amino acids (BCAAs) which are used as building blocks for protein and energy in muscle. We aim to explore how oral supplements of BCAAs might improve muscle in this population. If this improves muscle mass, we also expect it may improve other outcomes.
Discovering New Biomarkers In Hepatocellular Carcinoma
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
Liver cancer is a leading cause of cancer death with increasing rates and a high mortality. The project will develop new methods to predict liver cancer risk and outcomes using circulating samples rather than invasive biopsies. Our data shows that tissue and cells shed specific blebs into the circulation and these can contain unique information about the tissue of origin. We propose a series of experiments to show that these circulating samples are able to predict risk and outcomes with liver
How Should Moderate Iron Overload In Haemochromatosis Be Managed?
Funder
National Health and Medical Research Council
Funding Amount
$113,237.00
Summary
My PhD studies hereditary haemochromatosis which causes iron accumulation in the body which can be treated by removing blood. Whilst those with very high iron levels require treatment, it is not clear if those with only moderately raised iron also need treatment. If this study shows there is no difference in outcomes between the groups treatment to normalise body iron versus those who do not normalise body iron, this will change current practice.
The prevalence of liver cirrhosis worldwide is rising due. The majority of the morbidity and mortality, which arises with cirrhosis, occurs due to the development of portal hypertension. In cirrhosis unexplained vasodilatation of the splanchnic circulation occurs contributing significantly to portal hypertension. I expect to confirm through my experiments that the ACE2/Ang 1-7/Mas axis (alternate RAS) is responsible for this vasodilatation and that antagonists targeting this system may have a ro ....The prevalence of liver cirrhosis worldwide is rising due. The majority of the morbidity and mortality, which arises with cirrhosis, occurs due to the development of portal hypertension. In cirrhosis unexplained vasodilatation of the splanchnic circulation occurs contributing significantly to portal hypertension. I expect to confirm through my experiments that the ACE2/Ang 1-7/Mas axis (alternate RAS) is responsible for this vasodilatation and that antagonists targeting this system may have a role in therapy.Read moreRead less